RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Neuro, Thanks. It sounds like Lilly has had quite a turnover in their CNS dept, between Schoepp and Fibiger both leaving in recent years.

BTW, just curious if you've heard anything through the grapevine about other companies possibly getting into the low impact area? I'm still wondering about the Glaxo AMPA compound GSK-729327 that apparently made it through Phase 1 going toward the Schizo Cognition indication. Glaxo also patented some benzamides several months ago, which I was surprised to see. Of course the way things are going with Cortex it may not matter either way, but just curious.

Thanks for any insights.